Title of article
Effect of LY293111 in combination with gemcitabine in colonic cancer
Author/Authors
Hennig، نويسنده , , Rene and Ding، نويسنده , , Xian-Zhong and Tong، نويسنده , , Wei-Gang and Witt، نويسنده , , Richard A. and Jovanovic، نويسنده , , Borko D and Adrian، نويسنده , , Thomas E، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
6
From page
41
To page
46
Abstract
New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option.
Keywords
Gemcitabine , Heterotopic xenografts , LY293111 , Colon cancer
Journal title
Cancer Letters
Serial Year
2004
Journal title
Cancer Letters
Record number
1806552
Link To Document